|Source:||The tubers of Corydalis yanhusuo|
|Biological Activity or Inhibitors:||1. Glaucine has antitussive activity.
2. Glaucine can inhibit the migration and invasion of human breast cancer cells by MMP-9 inhibitory activity, attenuating IκBα and NF-κB activities.
3. Glaucine can enhance LPS and zymosan-induced IL-10 production, indicative for their use in different acute and chronic inflammatory diseases, may be an anti-arthritic agent.
|Solvent:||Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: email@example.com
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||2.8135 mL||14.0675 mL||28.1349 mL||56.2699 mL||70.3373 mL|
|5 mM||0.5627 mL||2.8135 mL||5.627 mL||11.254 mL||14.0675 mL|
|10 mM||0.2813 mL||1.4067 mL||2.8135 mL||5.627 mL||7.0337 mL|
|50 mM||0.0563 mL||0.2813 mL||0.5627 mL||1.1254 mL||1.4067 mL|
|100 mM||0.0281 mL||0.1407 mL||0.2813 mL||0.5627 mL||0.7034 mL|
Mol Cell Biochem. 2015 May;403(1-2):85-94.
|Glaucine inhibits breast cancer cell migration and invasion by inhibiting MMP-9 gene expression through the suppression of NF-κB activation.[Pubmed: 25670016]|
|We demonstrate that Glaucine, an alkaloid isolated from the plant Corydalis turtschaninovii tuber (Papaveraceae), can inhibit the migration and invasion of human breast cancer cells. We further show that Glaucine significantly blocks phorbol 12-myristate 13-acetate (PMA)-induced MMP-9 expression and activity in a dose-dependent manner. Results from reporter gene and electrophoretic mobility shift assays revealed that Glaucine inhibits MMP-9 expression by suppressing activation of the nuclear transcription factor nuclear factor-κB (NF-κB). Moreover, Glaucine attenuates PMA-induced IκBα degradation and nuclear translocation of NF-κB. Finally, we also found that Glaucine inhibits invasion and MMP-9 expression in the highly metastatic MDA-MB-231 breast cancer cell line. Taken together, our findings indicate that the MMP-9 inhibitory activity of Glaucine and its abilities to attenuate IκBα and NF-κB activities may be therapeutically useful as a novel means of controlling breast cancer growth and invasiveness.|
Biochem Pharmacol. 2013 Nov 15;86(10):1497-506.
|Studies on the in vivo contribution of human cytochrome P450s to the hepatic metabolism of glaucine, a new drug of abuse.[Pubmed: 23988488]|
|Glaucine ((S)-5,6,6a,7-tetrahydro-1,2,9,10-tetramethoxy-6-methyl-4H-dibenzo [de,g]quinoline), main isoquinoline alkaloid of Glaucium flavum (Papaveraceae), is used as antitussive, but also as recreational drug of abuse. Glaucine was mainly metabolized by O- and N-demethylation to four isomers in rats. So far, only scarce pharmacokinetic data were available. The calibration mode for determination of the metabolite concentrations had no relevant impact on the estimation of in vivo hepatic clearance of Glaucine. As Glaucine was metabolized via three initial steps and different P450 isoforms were involved in the hepatic clearance of Glaucine, a clinically relevant interaction with single inhibitors should not be expected.|
Immunopharmacol Immunotoxicol. 2015 Feb;37(1):56-62.
|Acetylated derivative of glaucine inhibits joint inflammation in collagenase-induced arthritis.[Pubmed: 25328086]|
|In the present study, we investigated the effect of acetylated derivative of plant alkaloid Glaucine (ADG) on experimental OA in mice. MATERIALS AND METHODS: Arthritis was induced by two intraarticular (i.a.) injections of collaganase. RESULTS: We established that Glaucine significantly decreased cell infiltration (2.32 ± 0.14 versus 1.62 ± 0.13), cartilage loss (2.42 ± 0.12 versus 1.12 ± 0.10) and bone erosion (1.76 ± 0.13 versus 1.04 ± 0.14) in arthritic mice. It appeared that the substance inhibited in a dose-dependent manner osteoclast differentiation in vitro. Glaucine suppressed the expression of pJAK2 in the joint and partially affected the expression of pSTAT3. CONCLUSION: Present results suggest that Glaucine is a suitable candidate for further development as an anti-arthritic agent.|
Fitoterapia. 2009 Oct;80(7):411-4.
|Toll-like receptor-mediated anti-inflammatory action of glaucine and oxoglaucine.[Pubmed: 19481591]|
|Two isochinoline alkaloids, Glaucine and oxoGlaucine were investigated for their suggested anti-inflammatory influence concerning nitric oxide and cytokine production. Mouse peritoneal macrophages were stimulated with different Toll-like receptor (TLR) ligands such as LPS for TLR4, zymosan for TLR2 and CpG for TLR9. The alkaloids inhibited TNF-alpha and IL-6 production induced by these ligands. In regard to IL-12 suppressive effect was registered in the case of CpG stimulation. Glaucine succeeded to enhance LPS and zymosan-induced IL-10 production. The reduction of pro-inflammatory cytokines and increase of anti-inflammatory IL-10 are indicative for their use in different acute and chronic inflammatory diseases.|